AstraZeneca Results Presentation Deck

Early pipeline news flow (1/2) Next key milestone by project Oncology Project 37 adavosertib ceralasertib oleclumab MEDI5752 AZD5991 AZD0466 AZD8205 AZD5305 AZD0171+ Imfinzi AZD7789 AZD2936 AZD4573 Target WEE1 ATR CD73 PD-1/ CTLA4 MCL1 Bcl-2/xL B7H4 ADC PARP1 sel anti-LIF mAb + PD-L1 PD-1/TIM3 PD-1/TIGIT CDK9 Phase || || || 1/11 트 1/11 || 1/11 1/11 = 1/11 1 || Indication uterine, pancreatic cancer solid tumours blood cancers solid tumours solid tumours blood cancers blood cancers solid tumours solid tumours NSCLC NSCLC NSCLC blood cancers Next milestone Phase III start Phase II data, 2023+ Phase II data, 2023 Phase I/II data, 2023+ Phase I/II data, 2023+ Phase II data, 2023+ Phase I/II data, 2023+ Phase I/II data, 2023+ Phase II data, 2023+ Phase I/II data, 2023+ Phase I data, 2023+ Phase II data, 2023 BioPharmaceuticals: CVRM Project cotadutide cotadutide AZD4831 AZD5718 AZD9977 + Farxiga zibotentan + Farxiga AZD2693 AZD8233 tozorakimab Target GLP-1/ glucagon GLP-1/ glucagon MPO FLAP MCR + SGLT2 ETR + SGLT2 PNPLA3 PCSK9 IL-33 Phase || || II/III || || || | || || Indication NASH DKD HFpEF CKD HF with CKD CKD NASH dyslipidaemia DKD Next milestone Phase III start, H2 2022 Phase II data, H1 2022 Phase II/III data, 2023+ Phase II data, 2023 Phase II data, 2023 Phase II data, H2 2022 Phase I data, H1 2022 Phase II data, H2 2022 Phase II data, 2023 B

View entire presentation